|
Mar 19
|
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
|
Mar 13
|
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
|
|
Mar 7
|
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
|
|
Mar 6
|
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
|
|
Jan 8
|
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
|
|
Dec 22
|
Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules
|
|
Dec 18
|
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions
|
|
Nov 30
|
Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC
|
|
Nov 29
|
Health Care Roundup: Market Talk
|
|
Nov 28
|
Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q
|